|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2009-2-24
|
|
pubmed:abstractText |
Among the relatively large number of known tumor-associated antigens (TAA) which are recognized by human CD8 T-cells, Melan-A/MART-1 is one of the most-if not the most-frequently used target for anti-cancer vaccines in HLA-A2 + melanoma patients. In this study, we analyzed the killing of a large panel of melanoma cells by a high avidity, MART-1-specific T-cell clone or a MART-1-specific, polyclonal T-cell culture. Strikingly, we observed that the MART-1-specific T-cells only killed around half of the analyzed melanoma cell lines. In contrast a Bcl-2-specific T-cell clone killed all melanoma cell lines, although the T-cell avidity of this clone was significantly lower. The MART-1-specific T-cell clone expressed NKG-2D and was fully capable of releasing both perforin and Granzyme B. Notably, the resistance to killing by the MART-1-specific T-cells could be overcome by pulsing of the melanoma cells with the MART-1 epitope. Thus, the very frequently used MART-1 epitope was not expressed on the surface of many melanoma cell lines. Our data emphasize that the selected tumor antigens and/or epitopes are critical for the outcome of anti-cancer immunotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Surface,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes, T-Lymphocyte,
http://linkedlifedata.com/resource/pubmed/chemical/Granzymes,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A2 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Immunodominant Epitopes,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/KLRK1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/MART-1-Melan-A(27-35) epitope,
http://linkedlifedata.com/resource/pubmed/chemical/NK Cell Lectin-Like Receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/PRF1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Pore Forming Cytotoxic Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1432-0851
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
58
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
665-75
|
|
pubmed:meshHeading |
pubmed-meshheading:18828018-Antigens, Neoplasm,
pubmed-meshheading:18828018-Antigens, Surface,
pubmed-meshheading:18828018-Cell Line, Tumor,
pubmed-meshheading:18828018-Cytotoxicity, Immunologic,
pubmed-meshheading:18828018-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:18828018-Epitopes,
pubmed-meshheading:18828018-Epitopes, T-Lymphocyte,
pubmed-meshheading:18828018-Granzymes,
pubmed-meshheading:18828018-HLA-A2 Antigen,
pubmed-meshheading:18828018-Humans,
pubmed-meshheading:18828018-Immunodominant Epitopes,
pubmed-meshheading:18828018-Interferon-gamma,
pubmed-meshheading:18828018-Melanoma,
pubmed-meshheading:18828018-NK Cell Lectin-Like Receptor Subfamily K,
pubmed-meshheading:18828018-Neoplasm Proteins,
pubmed-meshheading:18828018-Pore Forming Cytotoxic Proteins,
pubmed-meshheading:18828018-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:18828018-T-Lymphocytes, Cytotoxic
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines.
|
|
pubmed:affiliation |
Department of Hematology, Center for Cancer Immune Therapy (CCIT), Herlev University Hospital, Herlev, Denmark.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
